Bioniche Life Sciences Inc. 25 Years
Contact Us Careers
Home Newsroom
In the News

September 16, 2014
Bioniche Files Final Prospectus For Equity Offering

August 22, 2014
Bioniche Life Sciences Announces Terms of $5 Million Financing & Use of Proceeds


Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Management Team

Dr. Michael Berendt
Chief Executive Officer & Chief Scientist

Debi Butler
Vice-President and Corporate Controller

Monique Champagne
Vice-President, Clinical Research

Mohamed Elrafih
Vice-President, Manufacturing Operations

Brian Ford
Chief Financial Officer

Donald Olds
Chief Operating Officer

Senior Management Biographies

Dr. Michael BerendtDR. MICHAEL BERENDT
CEO & Chief Scientist, Bioniche Life Sciences Inc.

Dr. Michael Berendt was appointed as CEO of the Company on November 4, 2013.

  • In 2006, he became the President & CEO of Aegera, which was sold to Pharmascience in 2011
  • Worked in the U.S. research departments of Pfizer, Inc. and Bayer Corporation before becoming Managing Director, Life Sciences Sector of AEA Investors, then Managing Director of Research Corporation Technologies
  • Dr. Berendt graduated with a B.S. from Ohio Dominican University, a M.S. from Miami University, and a Ph.D. in Medical Microbiology and Immunology from Drexel University.
  • Dr. Berendt is a Director on the Boards of Waters Corporation and NeoMed Institute.
  • He serves as Executive Chairman of Anchor Therapeutics and serves as Chairman of Alethia Biothérapeutiques.


Vice-President and Corporate Controller

  • Is a Certified General Accountant
  • Received her Honours Bachelor of Commerce degree from Laurentian University
  • Joined Bioniche in 2000, holding increasingly responsible roles in the Finance Department before being appointed as Corporate Controller in 2009. She was promoted to Vice-President and Corporate Controller in 2012.
  • Has more than 30 years of accounting experience gained in the fields of banking, public accounting, and both private and publicly traded companies.


Vice-President, Clinical Research

  • Joined Bioniche in March, 2006 as Director, Clinical Research with 19 years of experience in international research
  • Held research and development management positions at Xanthus Life Sciences, Supratek Pharma Inc., PriceWaterhouseCoopers, Quintiles Canada, Wyeth-Ayerst Research and Scat Canada Inc.
  • Received a Masters degree in Pharmaceutical Science and a Bachelors degree in Pharmacy both from the University of Montréal.


Vice-President, Manufacturing Operations

  • Graduated from the University of Western Ontario with a Bachelor's Degree in Science (Microbiology).
  • Has more than 19 years' experience in the pharmaceutical industry.
  • Joined Bioniche in 1984 and became Vice-President, Manufacturing Operations in November, 2001.
  • Responsible for all manufacturing and plant operations for BLSI.


Chief Financial Officer

  • Has a Graduate Diploma in Accounting from the University of McGill and a B.A. (Economics, History, English) from the University of Guelph; is a member of the Ontario Institute of Chartered Accountants.
  • Has more than 26 years of experience serving private corporations and publicly traded entities.
  • Held increasingly responsible positions with Ernst & Young, with his last position being Principal of Business Risk Services in the firm's Toronto office
  • Prior to joining Bioniche Life Sciences Inc. in September, 2009, was Proprietor of PetersFord Consulting, a firm focused on finance and business risk services.


Chief Operating Officer

  • Holds a B.Sc. from the University of British Columbia, as well as a M.Sc. and a MBA from McGill University.
  • Appointed in January, 2014.
  • Was President & CEO of Presagia Corp. (Montreal, Quebec) prior to joining Bioniche. Previously served as Chief Operating Officer and Chief Financial Officer at Aegera Therapeutics (Montreal, Quebec) and Vice-President and Director at TD Securities, among other executive positions.
  • Has executive level experience in biotechnology, investment banking, and information technology, where he has led successful licensing, merger and acquisition, and debt and equity transactions for both public and private companies.
  • Is Chairman of the Board of the Neomed Institute, Director and Chair of the Audit Committee of the Consortium Québécois sur la Découverte du Médicament, Director of Bellus Health, and Treasurer of Oxfam Quebec.


Copyright 2004, Bioniche Life Sciences Inc. All rights reserved  |  Legal Disclaimer  |  Privacy Policy